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Abstract
Objective: Thyroid hormones have been implicated to play a role in cardiovascular 
disease, along with studies linking thyroid hormone to kidney function. The aim of this 
study is to investigate whether kidney function modifies the association of subclinical 
thyroid dysfunction and the risk of cardiovascular outcomes.
Methods: In total, 5804 patients were included in the PROspective Study of Pravastatin 
in the Elderly at Risk (PROSPER). For the current analysis, 426 were excluded because 
of overt thyroid disease at baseline or 6 months, 266 because of inconsistent thyroid 
function at baseline and 6 months, 294 because of medication use that could influence 
thyroid function, and 16 because of missing kidney or thyroid values. Participants with 
normal fT4 were classified, based on TSH both at inclusion and 6 months, into three 
groups: subclinical hypothyroidism (TSH >4.5 mIU/L); euthyroidism (TSH = 0.45–4.5 
mIU/L); and subclinical hyperthyroidism (TSH <0.45 mIU/L). Strata of kidney function 
were made based on estimated glomerular filtration rate into three clinically relevant 
groups: <45, 45–60, and >60 mL/min/1.73 m2. The primary endpoint consists of death 
from coronary heart disease, non-fatal myocardial infarction and (non)fatal stroke.
Results: Mean age was 75.3 years, and 49.0% patients were male. Mean follow-up was 
3.2 years. Of all participants, 109 subjects (2.2%) had subclinical hypothyroidism, 4573 
(94.0%) had euthyroidism, and 182 (3.7%) subclinical hyperthyroidism. For patients with 
subclinical hypothyroidism, euthyroidism, and subclinical hyperthyroidism, primary 
outcome occurred in 9 (8.3%), 712 (15.6%), and 23 (12.6%) patients, respectively. No 
statistically significant relationship was found between subclinical thyroid dysfunction 
and primary endpoint with adjusted hazard ratios of 0.51 (0.24–1.07) comparing 
subclinical hyperthyroidism and 0.90 (0.58–1.39) comparing subclinical hypothyroidism 
with euthyroidism. Neither was this relationship present in any of the strata of kidney 
function, nor did kidney function interact with subclinical thyroid dysfunction in the 
association with primary endpoint (P interaction = 0.602 for subclinical hyperthyroidism 
and 0.388 for subclinical hypothyroidism).
Conclusions: In this secondary analysis from PROSPER, we found no evidence that the 
potential association between thyroid hormones and cardiovascular disease is modified by 
kidney function in older patients with subclinical thyroid dysfunction.
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Introduction
Subclinical hyperthyroidism has been linked to atrial 
fibrillation and coronary artery calcification, whereas 
subclinical hypothyroidism has been associated with 
hypercholesterolemia and atherosclerosis (1, 2). Despite 
these observations, data from large prospective cohorts 
regarding thyroid function and cardiovascular events 
and mortality are conflicting (3, 4). The discrepancies 
between the study results may be explained by a small 
number of participants with subclinical thyroid disease 
and variations in the definitions of subclinical thyroid 
disease among different studies. In an attempt to tackle 
these limitations, recent large, individual participant 
data meta-analyses were performed and associations 
were found between increasing thyroid-stimulating 
hormone (TSH) levels and increased risk of stroke, high 
circulating free thyroxin (fT4) and increased risk of 
atrial fibrillation, and subclinical hypo- and 
hyperthyroidism and increased risk of coronary heart 
disease and mortality (5, 6, 7).
Chronic kidney disease (CKD) is accompanied by a 
substantial cardiovascular disease risk (8, 9). Associations 
of thyroid hormones and CKD have also been described. 
Multiple cross-sectional studies have linked lower 
thyroid function to a lower estimated glomerular 
filtration rate (eGFR) and increased prevalence of 
CKD (10, 11, 12). Longitudinal studies have presented 
conflicting results, linking kidney function decline to 
low (13) or high thyroid function (14). Whereas a recent 
individual participant data analysis found no role for 
thyroid hormones in renal function decline, it does not 
exclude reverse causality, indicating that previously 
found cross-sectional associations between kidney 
and thyroid may be explained by kidney dysfunction 
causing thyroid hormone changes (15). Whether or 
not kidney function causally alters thyroid hormones, 
several studies have shown an increased prevalence of 
subclinical thyroid disease and nonthyroidal illness in 
patients with CKD (16, 17), and this may be associated 
with higher mortality (18).
We hypothesize that there might be a role for kidney 
function in the relation between thyroid function and 
clinical cardiovascular outcomes, which may partly 
explain the conflicting results from large observational 
studies. Therefore, the aim of this study is to investigate 
whether kidney function modifies the association 
of subclinical thyroid dysfunction and the risk of 
cardiovascular outcomes in older patients.
Materials and methods
All subjects were participants of the ‘PROspective study 
of Pravastatin in the Elderly at Risk’ (PROSPER), a double-
blind, randomized, placebo-controlled trial, designed 
to investigate the relationship between statin treatment 
and the risk of cardiovascular and cerebrovascular 
events. In summary, 5804 older participants (70–82 
years) were enrolled in Ireland, Scotland, and The 
Netherlands. Patients were included if they had a history 
of, or an increased risk for, vascular disease and a baseline 
cholesterol between 4.0–9.0 mmol/L. A history of vascular 
disease included stroke, transient ischemic attack, 
myocardial infarction, arterial surgery, or amputation 
for vascular disease less than 6 months before study 
entry. Increased risk for vascular disease included current 
smoking, hypertension, diabetes mellitus or fasting blood 
glucose levels over 7 mmol/L. Detailed description of this 
population, including all in- and exclusion criteria, has 
been published previously (19). The study was approved 
by the institutional ethics review boards of centres of 
Cork University (Ireland), Glasgow University (Scotland), 
and Leiden University Medical Center (The Netherlands). 
Consent has been obtained from each patient or subject 
after full explanation of the purpose and nature of all 
procedures used.
Thyroid function
TSH was measured at baseline in all participants and fT4 
levels were only determined in case of abnormal TSH 
levels. Measurements were performed in three accredited 
laboratory centers (Cork in Ireland, Glasgow in Scotland, 
and Leiden in The Netherlands). TSH and fT4 levels were 
measured using state-of-the-art immunoassays (third-
generation assays with a functional sensitivity <0.05 
mIU/L). For both measurements, estimated inter- and 
intra-assay coefficients of variation were less than 5%. 
TSH and fT4 were determined in all participants after 6 
months of follow-up in available frozen plasma samples, 
which were stored at the University of Glasgow. The same 
electrochemiluminescence immunodetection method on 
a Roche Elecsys 2010 was used. The limits of detection 
were <0.005 mIU/L for TSH and 0.3 pmol/L for free T4. A 
reference range between 0.45 and 4.50 mIU/L was used for 
TSH and 12–22 pmol/L for fT4.
Participants with overt hyperthyroidism or 
hypothyroidism were excluded from the initial PROSPER 
trial. In the current study, participants were excluded 
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when biochemical data regarding TSH was missing. In 
addition, participants using antithyroid medication, 
thyroxine supplementation, amiodarone, or lithium 
were also excluded from the final analyses, see Fig. 1. 
Participants were classified into three groups: subclinical 
hyperthyroidism, euthyroidism, and subclinical 
hypothyroidism. Subclinical hyperthyroidism was 
defined at TSH levels <0.45 mIU/L with normal fT4 levels. 
Euthyroidism was defined as normal TSH levels (0.45–
4.5 mIU/L). Subclinical hypothyroidism was defined as 
TSH levels >4.5 mIU/L with normal fT4 levels.
Subclinical thyroid dysfunction may spontaneously 
resolve over time (20), and euthyroid participants 
may have developed subclinical thyroid dysfunction 
during the study follow-up period. As only participants 
with persistent subclinical thyroid dysfunction are of 
interest in this study, participants with the same thyroid 
function classification, based on TSH, at both baseline 
and 6 months of follow-up were included in the final 
study population.
Kidney function
Serum creatinine levels were measured at central 
laboratories, one in each of the three participating countries. 
Participants with baseline creatinine levels over 200 µmol/L 
were excluded from PROSPER and for the current study, 
and participants were also excluded when biochemical data 
were missing regarding kidney function. GFR was estimated 
using the Modification of Diet in Renal Disease equation: 
eGFR = 186 × Scr(−1.154) × age(−0.203) (×0.742 (if female)), where 
Scr denotes serum creatinine level in mg/dL. It is assumed 
that all participants were of Northern European descent 
(21). Participants were stratified by eGFR into three clinically 
relevant groups: eGFR <45 mL/min/1.73 m2, eGFR 45–60 
mL/min/1.73 m2, and eGFR >60 mL/min/1.73 m2 (22).
Endpoint
The primary endpoint of PROSPER is a combined end-
point which consists of death from coronary heart disease, 
Figure 1
Flowchart of study population. Inclusion and 
exclusion criteria of the current substudy of 
PROSPER (the PROspective Study of Pravastatin in 
the Elderly at Risk).
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non-fatal myocardial infarction, and fatal or non-fatal 
stroke. All clinical endpoints were adjudicated by an 
expert study endpoints committee blinded to randomised 
study medication and using predefined criteria.
Statistical analysis
Baseline characteristics were reported for the three 
different classifications of thyroid function. Data are 
presented as mean ± s.d. or median (interquartile range) 
depending on the distribution of data. One-way ANOVA, 
Kruskal Wallis, or Pearson chi-square tests were used 
to assess differences in baseline characteristics. Cox 
proportional hazard analysis was performed to assess the 
risk of the primary endpoint attributed to subclinical 
thyroid dysfunction within different subgroups of eGFR, 
including an interaction analysis between thyroid function 
and kidney function and the risk of primary endpoint. 
Analyses were adjusted for multiple prespecified variables 
including country, age, gender, use of pravastatin, history 
of vascular disease, history of diabetes mellitus, history 
of hypertension, current smoking, alcohol in units/week, 
BMI, total cholesterol/HDL ratio, and albumin. The data 
were analysed using IBM SPSS Statistics, version 23. P 
values were considered statistically significant if lower 
than 0.05 for baseline characteristics and hazard ratios 
(HR, 95% CI), or lower than 0.10 for interaction analyses.
Role of the funding sources
The Prospective Study of Pravastatin in the Elderly at 
Risk (PROSPER) trial was supported by an unrestricted 
investigator-initiated grant from Bristol-Myers Squibb, 
USA. The funding source had no involvement in study 
design; in the collection, analysis, and interpretation 
of data; in writing of the report; and in the decision to 
submit the paper for publication.
Results
Of the 5804 randomised participants, 4864 were 
suitable for inclusion in the current analysis (Fig. 1 and 
Supplementary materials, see section on supplementary 
materials given at the end of this article). A proportion of 
the participants with subclinical thyroid dysfunction had a 
spontaneous resolution when biochemical measurements 
were repeated after 6 months or vice versa (5.2%). 
Participants had a mean age of 75.3 years and 49.0% were 
male. Mean follow-up was 3.2 years. Of all participants, 
109 subjects (2.2%) had subclinical hypothyroidism, 4573 
(94.0%) had euthyroidism, and 182 (3.7%) subclinical 
hyperthyroidism.
Baseline characteristics are shown in Table 1 per 
thyroid function group and overall. Age and gender were 
comparable between groups. Furthermore, eGFR category 
did not differ (P = 0.417). A history of vascular disease 
was present in 33 (30.3%), 2059 (45.0%), and 69 (37.9%) 
patients with subclinical hyperthyroidism, euthyroidism, 
and subclinical hypothyroidism, respectively (P = 0.002). 
Use of pravastatin, beta-blockers, and antiarrhythmics were 
comparable. Patients with subclinical hyperthyroidism 
had highest blood pressure, both systolic with a mean 
difference of 6 mmHg (P = 0.015) and diastolic with a 
mean difference of 3 mmHg (P = 0.001).
Subclinical thyroid dysfunction
Table 2 shows the univariate and multivariate association 
between thyroid function groups and the primary endpoint. 
Primary endpoint occurred in 9 (8.3%), 712 (15.6%), and 
23 (12.6%) patients with subclinical hyperthyroidism, 
euthyroidism, and subclinical hypothyroidism, 
respectively. Multivariate adjusted HRs (95% CI) were 0.51 
(0.24–1.07) comparing subclinical hyperthyroidism with 
euthyroidism and 0.90 (0.58–1.39) comparing subclinical 
hypothyroidism with euthyroidism.
The univariate and multivariate association of thyroid 
status with primary endpoint over strata of baseline eGFR 
category is shown in Table 3. In the prespecified eGFR 
categories 656 subjects (13.5%) had an eGFR <45 mL/
min/1.73 m2, 1933 (39.7%) 45-60 mL/min/1.73 m2, and 
2275 (46.8%) >60 mL/min/1.73 m2. The levels of TSH and 
fT4 did not differ between this categories. Mean ± s.e. TSH 
was 2.1 ± 0.06; 2.1 ± 0.03; and 2.0 ± 0.03 in patients with 
eGFR <45 mL/min/1.73 m2; eGFR 45–60 mL/min/1.73 m2; 
and eGFR >60 mL/min/1.73 m2, respectively (P = 0.383). 
Mean ± s.e. fT4 was 16.4 ± 0.3; 16.5 ± 0.1; and 16.7 ± 0.1 in 
patients with eGFR <45 mL/min/1.73 m2; eGFR 45–60 mL/
min/1.73 m2; and eGFR >60 mL/min/1.73 m2, respectively 
(P = 0.413). When comparing subclinical hyperthyroidism 
with euthyroidism, multivariate adjusted HRs (95% 
CI) were 1.07 (0.26–4.40), 0.25 (0.03–1.76), and 0.54 
(0.20–1.45) in eGFR <45 mL/min/1.73 m2, 45–60 mL/
min/1.73 m2, and >60 mL/min/1.73 m2, respectively, 
without a significant interaction (P interaction = 0.602). 
When comparing subclinical hypothyroidism with 
euthyroidism multivariate adjusted HRs (95% CI) were 
1.41 (0.57–3.51), 0.24 (0.06–0.95), and 1.43 (0.83–2.46) 
in eGFR <45 mL/min/1.73 m2, 45–60 mL/min/1.73 m2, 
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and >60 mL/min/1.73 m2, respectively, also without a 
significant interaction (P-interaction = 0.388).
Discussion
In this secondary analysis of the PROSPER study, we 
aimed to explore whether kidney function explains 
the association of thyroid function and the risk of 
cardiovascular events. In these older patients at high risk of 
cardiovascular disease, no relationship was found between 
subclinical thyroid dysfunction and cardiovascular events, 
nor was this relationship present after stratification by 
kidney function. Furthermore, kidney function did not 
interact with subclinical thyroid dysfunction in relation 
with cardiovascular events.
Table 1 Baseline characteristics split by baseline thyroid status and overall.
Subcl hyperth 
(n = 109)
Euthyroidism  
(n = 4573)
Subcl hypoth  
(n = 182) Total (n = 4864) P value
Age (years; mean ± s.d.) 74.7 ± 3.2 75.3 ± 3.4 75.2 ± 3.5 75.3 ± 3.4 0.160
Male gender, n (%) 64 (58.7) 2226 (48.7)  95 (52.2) 2385 (49.0) 0.080
Education (years; mean ± s.d.) 15.1 ± 1.9 15.1 ± 2.1 15.1 ± 2.1 15.1 ± 2.1 0.966
History of hypertension, n (%) 70 (64.2) 2804 (61.3) 110 (60.4) 2984 (61.3) 0.801
History of diabetes, n (%) 9 (8.3)  490 (10.7)  20 (11.0) 519 (10.7) 0.706
History of vascular disease, n (%) 33 (30.3) 2059 (45.0) 69 (37.9) 2161 (44.4) 0.002
eGFR categories, n (%) 0.417
 <45 mL/min/1.73 m2 14 (12.8)  615 (13.4) 27 (14.8) 656 (13.5)
 <45–60 mL/min/1.73 m2 35 (32.1) 1830 (40.0) 68 (37.4) 1933 (39.7)
 >60 mL/min/1.73 m2 60 (55.0) 2128 (46.5) 87 (47.8) 2275 (46.8)
Smoking status, n (%) 0.665
 Never 32 (29.4) 1545 (33.8) 54 (29.7) 1631 (33.5)
 Former 46 (42.2) 1776 (38.8) 73 (40.1) 1895 (39.0)
 Current 31 (28.4) 1252 (27.4) 55 (30.2) 1338 (27.5)
Alcohol in units/week, n (%)  6.2 ± 9.2 5.3 ± 9.3 6.4 ± 12.1 5.3 ± 9.4 0.173
Medication use, n (%)
 Pravastatin 56 (51.4) 2292 (50.1) 90 (49.5) 2438 (50.1) 0.951
 Aspirin 28 (25.7) 1672 (36.6) 61 (33.5) 1761 (36.2) 0.049
 Βeta-blockers 25 (22.9) 1191 (26.0) 58 (31.9) 1274 (26.2) 0.159
 Antiarrhythmics 3 (2.8) 117 (2.6)              4 (2.2) 124 (2.5) 0.946
Objective measures (mean ± s.d.)
 SBP (mmHg) 161 ± 21 155 ± 22 155 ± 21 155 ± 22 0.015
 DBP (mmHg)  88 ± 10 84 ± 12  84 ± 10  84 ± 12 0.001
 BMI (kg/m2) 26.5 ± 4.3 26.8 ± 4.2 26.6 ± 4.0 26.8 ± 4.2 0.552
 Total cholesterol/HDL-ratio 
(mmol/L)
 4.7 ± 1.3 4.7 ± 1.3  4.7 ± 1.3  4.7 ± 1.3 0.967
 Glucose (mmol/L)  5.4 ± 1.2 5.5 ± 1.5  5.5 ± 1.2  5.5 ± 1.5 0.922
 CRP (mg/L)  4.0 ± 5.1 4.2 ± 6.5  3.7 ± 5.4  4.2 ± 6.5 0.560
 Urea (mg/dL)  6.3 ± 1.8 6.3 ± 1.8  6.2 ± 1.6  6.3 ± 1.8 0.627
 Hb (mmol/L)  8.9 ± 0.7 8.7 ± 0.8  8.8 ± 0.8  8.7 ± 0.8 0.018
BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; Hb, haemoglobin; HDL, high-density lipoprotein; SBP, systolic blood 
pressure; s.d., standard deviation; Subcl hyper, subclinical hyperthyroidism; Subl hypo, subclinical hypothyrodism.
Table 2 Univariate and multivariate influence of thyroid status on the primary endpointa.
Thyroid status based on TSH at baseline and 6 months
Subcl hyperth vs euth (n = 109 vs 4573) Subcl hypo vs euth (n = 182 vs 4573)
No. of events (%) 9 (8.3) vs 712 (15.6) 23 (12.6) vs 721 (15.6)
Univariate HR (95% CI) 0.52 (0.27–1.00) 0.80 (0.52–1.22)
Age and sex adjusted HR (95% CI) 0.52 (0.27–0.99)b 0.30 (0.53–1.22)
Multivariate adjusted HR (95% CI) 0.51 (0.24–1.07) 0.90 (0.58–1.39)
Multivariate adjusted analysis include prespecified variables: country, age, gender, use of pravastatin, history of vascular disease, history of diabetes 
mellitus, history of hypertension, current smoking, alcohol in units/week, BMI, total cholesterol/HDL-ratio, albumin.
aPrimary endpoint includes coronary heart disease death or non-fatal myocardial infarction or fatal or non-fatal stroke; bP-value of hazard ratio <0.05.
CI, confidence interval; HR, hazard ratio.
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International License.https://doi.org/10.1530/EC-19-0502
https://ec.bioscientifica.com © 2020 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 04/29/2020 11:15:27AM
via free access
L E Zijlstra et al. Kidney and thyroid in 
cardiovascular disease
60
PB–8
9:1
Although the association of thyroid dysfunction on 
cardiovascular events and mortality has been studied 
in patients with CKD (23, 24), this is the first time this 
association has been studied over different strata of CKD 
to explore a possible interaction between thyroid and 
kidney function, which we did not find.
There are two hypotheses regarding the interaction 
of kidney and thyroid. First, thyroid hormone changes 
may predispose to kidney dysfunction, due to possible 
alterations in kidney hemodynamics and structure, both 
direct and indirect via the cardiovascular system (25). 
Secondly, kidney dysfunction may predispose to thyroid 
hormone changes, via influence on the metabolism of 
thyroid hormones or due to chronic illness (as CKD) 
leading to nonthyroidal illness as potential underlying 
pathophysiological mechanisms (23, 26). A recent 
individual participant data analysis from 16 independent 
cohorts of the Thyroid Studies Collaboration found no 
role for thyroid hormones in kidney dysfunction (15). 
However, it does not exclude that previously found cross-
sectional associations between kidney and thyroid (10, 
11) may be explained by kidney dysfunction causing 
thyroid hormone changes. Another explanation could be 
that there might be a common pathway to thyroid and 
kidney dysfunction, due to shared cardiovascular risk 
factors, especially in older people.
The prevalence of subclinical thyroid dysfunction 
within this study (2.2% patients with subclinical 
hypothyroidism and 3.7% with subclinical 
hyperthyroidism) was lower than the prevalence of 
subclinical thyroid dysfunction among the general 
population within the same geographical location (27). In 
addition, contrary to what has been reported in literature, 
the prevalence of subclinical thyroid dysfunction did not 
change with increasing degrees of kidney dysfunction 
(28), nor did the levels of TSH and fT4 differ between 
groups stratified by kidney function (12).
Strengths and limitations
The presence of two thyroid measurements is a 
major strength which allowed us to more accurately 
assess subclinical thyroid disease by excluding those 
without persistent thyroid disease after 6 months of 
follow-up. In most studies regarding thyroid function 
and cardiovascular disease risk, all measurements are 
performed at baseline and compared to follow-up data. We 
showed that a proportion of participants with subclinical 
thyroid dysfunction have a spontaneous resolution when 
biochemical measurements are repeated after 6 months or 
vice versa (5.2%), explaining why for instance the TRUST 
study ‘Thyroid hormone Replacement for Untreated older 
adults with Subclinical hypothyroidism - a randomised 
placebo controlled Trial’ had a relatively long run-in phase, 
as patients with subclinical thyroid disease spontaneously 
resolved to euthyroidism before the trial started (20). 
Using two separate measurements, as in our study, thus 
filters the bias which is otherwise present in studies 
utilizing only baseline measurements. Furthermore, we 
excluded patients who used medication that could be of 
influence on thyroid function such as both thyroxin and 
antithyroid treatment, but also lithium and amiodaron, 
although amiodaron could have long-lasting effects and 
its previous use is unknown. Despite the large number 
of participants within the PROSPER study, the number 
of patients with subclinical thyroid dysfunction within 
Table 3 Univariate and multivariate influence of thyroid status on the primary endpointa split by baseline eGFR category.
eGFR <45, n = 656 eGFR 45–60, n = 1933 eGFR >60, n = 2275
Subcl hyperth vs euth 
(n = 14 vs 615)
Subcl hypo vs euth 
(n = 27 vs 615)
Subcl hyperth vs  
euth (n = 35 vs 1830)
Subcl hypo vs euth 
(n = 68 vs 1830)
Subcl hyperth vs 
euth (n = 60 vs 2128)
Subcl hypo vs euth 
(n = 87 vs 2128)
No. of  
events (%)
6 (33.3) vs 123 (18.8) 8 (20.5) vs 123 (18.8) 4 (12.9) vs 280 (15.0) 8 (7.8) vs 280 (15.0) 4 (9.8) vs 338 (16.0) 16 (13.0) vs 338 (16.0)
Univariate HR 
(95% CI)
0.72 (0.18–2.93) 1.13 (0.50–2.56) 0.37 (0.09–1.47) 0.28 (0.09–0.88)b 0.55 (0.23–1.33) 1.10 (0.64–1.87)
Age and sex 
adjusted HR 
(95% CI)
0.79 (0.20–3.12) 1.18 (0.52–2.69) 0.36 (0.09–1.43) 0.27 (0.09–0.86)b 0.54 (0.22–1.31) 1.10 (0.65–1.89)
Multivariate 
adjusted HR 
(95% CI)
1.07 (0.26–4.40) 1.41 (0.57–3.51) 0.25 (0.03–1.76) 0.24 (0.06–0.95)b 0.54 (0.20–1.45) 1.43 (0.83–2.46)
Multivariate adjusted analysis include prespecified variables: country, age, gender, use of pravastatin, history of vascular disease, history of diabetes 
mellitus, history of hypertension, current smoking, alcohol in units/week, BMI, total cholesterol/HDL-ratio, albumin.
aPrimary endpoint includes coronary heart disease death or non-fatal myocardial infarction or fatal or non-fatal stroke; bP-value of hazard ratio <0.05.
CI, confidence interval; HR, hazard ratio. 
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this study was relatively small, limiting the power to find 
an association between subclinical thyroid disease and 
cardiovascular events, and an interaction between thyroid 
and kidney function, to a smaller magnitude. Whereas 
one of the exclusion criteria was a high creatinine (>200 
µmol/L) at baseline, the influence of severe or end-stage 
CKD (eGFR <30 mL/min/1.73 m2) on the association of 
thyroid function and cardiovascular events is unknown. 
Furthermore, the larger proportion of euthyroid patients 
with a history of vascular disease compared to those 
with subclinical thyroid dysfunction may have masked 
the risk of cardiovascular events in subclinical thyroid 
dysfunction, but adjustment in linear regression models 
yielded similar results.
Conclusion
In this secondary analysis from PROSPER, kidney function 
did not interact in the association of thyroid function and 
cardiovascular disease. Therefore, we found no evidence 
that the potential association between thyroid hormones 
and cardiovascular disease is modified by kidney function 
in older patients with subclinical thyroid dysfunction.
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